Buy Rating for Astria Therapeutics: Promising Prospects in HAE and Atopic Dermatitis Markets
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...
ETF Daily News6d
Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) in a research report released on Thursday,Benzinga reports. HC Wainwright currently has a $ ...
Morningstar18d
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE
Strong Financial Position, Funded Through Expected Top-Line Phase 3 Results -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies ...
Business Wire1mon
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...
ETF Daily News1mon
Astria Therapeutics (NASDAQ:ATXS) Shares Down 3.4% – What’s Next?
Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) dropped 3.4% on Thursday .The stock traded as low as $9.22 and last traded at $9.22. Approximately 20,860 shares changed hands ...
Investing2d
Astria Therapeutics Inc (ATXS)
Astria Therapeutics recently reported its third-quarter financial results and provided a corporate update, highlighting its promising Phase 1a data for STAR-0215, a potential ...
Business Wire8d
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...
CNN3y
Astria Therapeutics, Inc.
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary ...